Exploring the Role of Immunotherapy in Advanced Non-Small Cell Lung Cancer Without Targetable Mutations

Exploring the Role of Immunotherapy in Advanced Non-Small Cell Lung Cancer Without Targetable Mutations

Join Hossein Borghaei, DO, MS, Ramaswamy Govindan, MD, Charu Aggarwal, MD, MPH, and Jarushka Naidoo, MBBCh in a discussion on the role of immunotherapy in advanced non-small cell lung cancer without targetable mutations.

This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.

The goal of this activity is that learners will have an increased awareness of immunotherapeutic regimens as first-line treatment for NSCLC and be better able to identify and manage immune-related adverse events using a multidisciplinary approach.
 


Learning Objectives:

  • Have increased knowledge regarding the
    • Rationale for using immunotherapy in early-stage NSCLC
    • Key clinical trial data evaluating immunotherapy in the treatment of early-stage NSCLC
  • Demonstrate greater confidence in their ability to
    • Understanding of the latest data on immunotherapy in the treatment of early-stage NSCLC

Approximate Time to Complete: 30 minutes

 

Credit Available: March 11, 2022 - March 11, 2023

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

Additional Resources for Clinicans from SITC:

 

 

Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the clinical trial data evaluating immunotherapy-containing regimens for frontline treatment of advanced non-small cell lung cancer (NSCLC) without actionable mutations.
  • Have increased knowledge regarding characteristics of dual immune checkpoint inhibitor therapy as frontline treatment for advanced NSCLC without actionable mutations.
  • Have greater competence related to tailoring frontline treatment for patients with advanced NSCLC without actionable mutations.
  • Demonstrate greater confidence in their ability to individualize frontline treatment for patients with advanced NSCLC without actionable mutations.
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.50
Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.50
Accreditation Council for Pharmacy Education
CEU: 0.50
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50